19 August 2022 - Crysvita is the first approved biologic treatment in the EU for patients with tumour-induced osteomalacia who cannot ...
18 August 2022 - Vegzelma offers European patients living with certain types of breast, lung, renal, colon, rectum, ovarian and cervical ...
18 August 2022 - Fresenius Kabi announced today that its marketing authorisation application for MSB11456, the company’s tocilizumab biosimilar candidate, ...
18 August 2022 - Oncopeptides today announces that the European Commission has granted Pepaxti (melphalan flufenamide) marketing authorisation in combination ...
18 August 2022 - Aeglea BioTherapeutics today announced that a marketing authorisation application for pegzilarginase for the treatment of arginase 1 ...
18 August 2022 - The EMA’s CHMP has started a review of a conditional marketing authorisation application for Skycovion, a ...
16 August 2022 - The EMA has published a draft agenda for this week's CHMP meeting. ...
11 August 2022 - Vyvgart is the first neonatal Fc receptor blocker approved in Europe for the treatment of adults living ...
9 August 2022 - It is the first all oral, fixed duration, once daily treatment based on a Bruton's tyrosine kinase ...
9 August 2022 - The EMA has started a rolling review of a variant-adapted COVID-19 vaccine from Pfizer and BioNTech, ...
4 August 2022 - First and only approved medicine targeting BRCA mutations in early breast cancer ...
1 August 2022 - SK bioscience will accelerate to apply for emergency use listing to the World Health Organization. ...
1 August 2022 - Pharming is on track to submit its marketing authorisation application for leniolisib in H2 2022. ...
29 July 2022 - Approval is supported by data from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which ...
28 July 2022 - The Big Data Steering Group set up by EMA and the Heads of Medicines Agencies has ...